Compare AbbVie Inc (ABBV) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Amylx Pharmaceuticals Inc — how do they compare? AbbVie Inc trades at $247.56 (market cap $441.94B), while Amylx Pharmaceuticals Inc trades at $23.78 (market cap $2.64B). The key difference: AbbVie Inc is far larger — about 167.4× Amylx Pharmaceuticals Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ABBV | AMLX | |
|---|---|---|
Market Cap | $441.94B | $2.64B |
Sector | Health | Health |
52-Week High | $263.58 | $24.19 |
52-Week Low | $197.38 | $7.82 |
Enterprise Value | $506.19B | $2.39B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
